CRNX News and Press, Crinetics Pharmaceuticals Inc. From 11/22/22

SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5 th Annual Evercore ISI HealthCONx Conference being held virtually November 29 &...

Crinetics Pharmaceuticals press release ( NASDAQ: CRNX ): Q3 GAAP EPS of -$0.78 beats by $0.03 . Revenue of $0.46M beats by $0.26M . For further details see: Crinetics Pharmaceuticals GAAP EPS of -$0.78 beats by $0.03, revenue of $0.46M beats by $0.26M

Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered and maintained IGF-1 at levels comparable to prior injected SRL therapy for up to 103 weeks in participants living with acromegaly participatin...

SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the completion of enrollment in the Phase 3 PATHFNDR-1 study . PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 studies evaluating the safety and efficacy of ...

SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX) today announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted CRN04777 an “Innovation Passport” for the treatment of congenital h...

SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer. Dr. Pizzuti is a board-certified physician with more than 30 years of pharmaceutical industry experience ...

SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will present a corporate overview at the H.C. Wainwright 24 th Annual Global Investment Conference being held September 12-14, 2022, both virtually and in-p...

Open label extension data from investigational compound paltusotine orally presented at the 35 th Brazilian Congress of Endocrinology and Metabolism Lowered and maintained IGF-1 at levels comparable to prior injected somatostatin receptor ligands (SRL) Genera...

SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT prog...

Crinetics Pharmaceuticals press release ( NASDAQ: CRNX ): Q2 GAAP EPS of -$0.81 misses by $0.15 . Revenue of $0.44M misses by $0.28M . Based on its current plans, the company expects that current cash, cash equivalents and short-term investments will fund its c...